|
Autosomal Recessive Polycystic Kidney Disease
|
0.070 |
Biomarker
|
disease |
BEFREE |
The genetic interaction was synergistic in both species, with digenic animals exhibiting phenotypes of rapidly progressive PKD and early lethality resembling classic ARPKD.
|
31427367 |
2019 |
|
Ciliopathies
|
0.030 |
Biomarker
|
disease |
BEFREE |
Primary cilia have been considered central to PKD pathogenesis due to protein localization and common cystic phenotypes in syndromic ciliopathies, but their relevance is questioned in the simple PKDs.
|
31427367 |
2019 |
|
Intelligence
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Pleiotropic Meta-Analysis of Cognition, Education, and Schizophrenia Differentiates Roles of Early Neurodevelopmental and Adult Synaptic Pathways.
|
31374203 |
2019 |
|
Schizophrenia
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Pleiotropic Meta-Analysis of Cognition, Education, and Schizophrenia Differentiates Roles of Early Neurodevelopmental and Adult Synaptic Pathways.
|
31374203 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Pharmacological activation of PKD counters SINGD and delays the onset of T2D.
|
31346174 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Protein kinase D1 (PKD1) is a serine/threonine kinase that belongs to the calcium/calmodulin-dependent kinase family, and is involved in multiple mechanisms implicated in tumor progression such as cell motility, invasion, proliferation, protein transport, and apoptosis.
|
31311827 |
2019 |
|
Carcinogenesis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
While it is expressed in most tissues in the normal state, PKD1 expression may increase or decrease during tumorigenesis, and its role in proliferation is context-dependent and poorly understood.
|
31311827 |
2019 |
|
Tumor Progression
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Protein kinase D1 (PKD1) is a serine/threonine kinase that belongs to the calcium/calmodulin-dependent kinase family, and is involved in multiple mechanisms implicated in tumor progression such as cell motility, invasion, proliferation, protein transport, and apoptosis.
|
31311827 |
2019 |
|
Schizophrenia
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Association of Schizophrenia Risk With Disordered Niacin Metabolism in an Indian Genome-wide Association Study.
|
31268507 |
2019 |
|
Polycystic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Discoidin Domain Receptor 1 (DDR1) tyrosine kinase is upregulated in PKD kidneys but does not play a role in the pathogenesis of polycystic kidney disease.
|
31260458 |
2019 |
|
Polycystic Kidney, Autosomal Dominant
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, genetic deletion of DDR1 using CRISPR/Cas9 failed to slow cyst growth or preserve kidney function in both a rapid and slow mouse model of ADPKD demonstrating that DDR1 does not play a role in PKD pathogenesis and is thus a not viable drug target.
|
31260458 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, the high levels of expression of PKD1, observed in highly proliferative cancers and tumors with poor prognosis, contribute to enhanced resistance to chemotherapy.
|
31167779 |
2019 |
|
Liver carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In this study, we show that the ER stress inducers tunicamycin and thapsigargin lead to the activation of PKD1 in human prostate cancer PC-3 cells and in hepatoma HepG2 cells through a PKCδ-dependent mechanism.
|
31167779 |
2019 |
|
Liver neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
In this study, we show that the ER stress inducers tunicamycin and thapsigargin lead to the activation of PKD1 in human prostate cancer PC-3 cells and in hepatoma HepG2 cells through a PKCδ-dependent mechanism.
|
31167779 |
2019 |
|
Mechanical Allodynia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
PKD and Gβγ inhibitors also attenuated protease-evoked mechanical allodynia in mice.
|
31142616 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, this study explained the molecular basis of PKD1 specific inhibition, which may help to design new selective inhibitors for better therapies to overcome cancer and PKD1 dysregulated disorders.
|
31131745 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, this study explained the molecular basis of PKD1 specific inhibition, which may help to design new selective inhibitors for better therapies to overcome cancer and PKD1 dysregulated disorders.
|
31131745 |
2019 |
|
Episodic Kinesigenic Dyskinesia 1
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
p53 mutation regulates PKD genes and results in co-occurrence of PKD and tumorigenesis.
|
31119048 |
2019 |
|
Carcinogenesis
|
0.040 |
GeneticVariation
|
phenotype |
BEFREE |
p53 mutation regulates PKD genes and results in co-occurrence of PKD and tumorigenesis.
|
31119048 |
2019 |
|
Polycystic Kidney, Autosomal Dominant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The 16 novel PKD gene mutation sites and two novel PKD2 gene mutation sites discovered in this study have some significance in genetic counseling for ADPKD patients, and increase the number of studied families and expand the mutation database of ADPKD.
|
31056860 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Protein kinase D1 (PKD1) plays a vital role in signal transduction, cell proliferation, membrane trafficking, and cancer; however, the majority of the studies up to date had centered primarily on PKD1 functions in interphase, very little is known about its role during cell division.
|
30997696 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Protein kinase D1 (PKD1) plays a vital role in signal transduction, cell proliferation, membrane trafficking, and cancer; however, the majority of the studies up to date had centered primarily on PKD1 functions in interphase, very little is known about its role during cell division.
|
30997696 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Protein Kinase D1 (PrKD1) functions as a tumor and metastasis suppressor in several human cancers by influencing cell-cycle progression.
|
30958903 |
2019 |
|
Neoplasm Metastasis
|
0.080 |
Biomarker
|
phenotype |
BEFREE |
Protein Kinase D1 (PrKD1) functions as a tumor and metastasis suppressor in several human cancers by influencing cell-cycle progression.
|
30958903 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Protein kinase D1 (PKD1) protects cells from oxidative stress, and its abnormal activity serves an important role in multiple malignancies.
|
30896865 |
2019 |